Tg Therapeutics

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

Tg therapeutics. TG Therapeutics, Inc. (NASDAQ:TGTX) TG Therapeutics, Inc. (NASDAQ:TGTX) closed at $23.96 on the last trading session with an increase of 0.63%, whereas, it previously closed at $23.81. The company has a market capitalization of $3.25 Billion. The company traded shares of 1.58 Million on the trading day while its three month average volume stands at 1.66 Million. Now to discuss some of the. TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s Lymphoma (NHL), and multiple sclerosis (MS). More Details TG Therapeutics, Inc. (NASDAQ:TGTX) has a beta value of 2.25 and has seen 2,350,885 shares traded in the last trading session. The company, currently valued at $3.25 Billion, closed the last trade at $25.64 per share which meant it gained $0.16 on the day or 0.63% during that session. TG Therapeutics to Present at Upcoming Investor Conferences. NEW YORK , Sept. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at two upcoming virtual investor conferences.

TG Therapeutics, Inc. (NASDAQ:TGTX) went up by 4.26% from its latest closing price when compared to the 1-year high value of $22.28 and move down -9.7%, while TGTX stocks collected +11.47% of gains with the last five trading sessions. TG Therapeutics earned $0.47 in the second quarter, compared to $0.42 in the year-ago quarter. The stock has a 52-week-high of $25.02 and a 52-week-low of $4.95. At the end of the last trading. TG Therapeutics Inc (TGTX) Q3 2019 Earnings Call Transcript Motley Fool Transcribers | Nov 12, 2019 TGTX earnings call for the period ending September 30, 2019. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is in late stage clinical development with two investigational compounds, ublituximab and umbralisib, the combination of which is referred to as.

TG Therapeutics, Inc. (NASDAQ:TGTX) went up by 1.82% from its latest closing price when compared to the 1-year high value of $24.76 and move down -1.98%, while TGTX stocks collected 1.93% of gains with the last five trading sessions. TG Therapeutics Inc (NASDAQ:TGTX) saw some unusual options trading activity on Monday. Investors purchased 4,470 call options on the stock. This is an increase of 100% compared to the typical daily volume of 2,235 call options. TG Therapeutics is well positioned to achieve their remaining milestones for this year and are looking forward for transition from a development stage company to a fully integrated commercial organization. TG Therapeutics’ Q2 financial report and the updates on the ongoing trials surely puts them at the top. TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs.

Get TG Therapeutics Inc (TGTX:NASDAQ) real-time stock quotes, news and financial information from CNBC. TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders. TG Therapeutics (TGTX) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody. TG Therapeutics will also host a reception on Monday, December 7th, 2015 beginning at 7:45pm ET, with featured presentations beginning promptly at 8:00pm ET. The event will take place at the Hyatt Regency Orlando in the Bayhill 17/18 Room.

NEW YORK , Aug. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and At TG we have big ideas, take bold actions and are fearless in our pursuit to develop the best possible treatment solutions for those with B-cell diseases. We are always looking for talented, passionate, and hard-working people to join our team and help us to realize our goals. We are currently recruiting for the below open positions. Trending now. TG Therapeutics 25.53 0.81 (3.28%). Watch Find the latest TG Therapeutics, Inc. (TGTX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.